Tamoxifen and fulvestrant, both explicitly classified as “estrogen receptor antagonists” in the Selleck database, function by inhibiting estrogen activity and suppressing the proliferation of breast cancer cells. This evidence concerns the gene ESR1 and breast carcinoma.